UFC Suspends Debutant Jorge Gonzalez For 2 Years Following Failed Drug Test

September 12, 2020 8:11 pm

Earlier today, the UFC released a statement regarding a failed drug test for Jorge Gonzalez Villa. The 36-year-old Mexican would have fought in July. However, as his opponent missed weight, the bout was canceled.

Villa was then set to fight on August 22 against Ike Villanueva. However, the fight was canceled as Villa was pulled out of the card when his test came back positive. 

A statement released by the UFC read, “Upon being added to the UFC anti-doping program, athletes are required to declare all medication and supplements they have used in the past 12 months. An athlete who declares the prior use of a prohibited substance will not be deemed to have committed a violation but, depending on the substance, may be required to refrain from competition for a period of at least six months and provide at least two negative samples. Gonzalez Villa did not declare the use of Stanozolol, drostanolone, or tamoxifen on his onboarding declaration forms.”

Jorge Gonzalez faces a lengthy ban ahead of him

Gonzalez’s last fight before joining  UFC was with the  “Ultimate Warrior Challenge” in Mexico.

He defeated Marcos Rodriguez via rear-naked choke. Prior to fighting in the UWC, Gonzalez was a part of various organizations such as Jasaji fighting league and Maximum Cage fighting among others.

The UFC, however, would’ve definitely been one of the bigger organizations he has fought for. Despite being given a fight almost immediately, he could not make his debut as his opponent missed weight

At 36 years of age, Gonzalez is definitely a veteran of the sport. However, a 2-year ban at 36 means he will be 38 before he is eligible to compete again, assuming he clears all tests henceforth. It is not presumptuous to assume that by the time his suspension ends, it could be too late for him to fight for a title or even win it. A fantastic opportunity squandered.

Continue the conversation on the app, join other MMA fans on MMA Fans App

Disqus Comments Loading...